Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Ireland
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Voxzogo (vosoritide) is a C-type natriuretic peptide analog designed to address the underlying growth plate signaling defect in achondroplasia, the most common form of disproportionate short stature.
Voxzogo is FDA-approved to increase linear growth in pediatric patients with achondroplasia who have open growth plates (epiphyses), following a 2023 expansion that extended eligibility beyond the original 5-years-and-older population to children of all ages with open growth plates.
Vosoritide mimics C-type natriuretic peptide, counteracting the overactive FGFR3 signaling that suppresses bone growth in achondroplasia, thereby supporting more typical bone growth at the growth plate.
The recommended dose is 15 mcg/kg administered subcutaneously once daily. Patients should be well hydrated and have eaten before administration to reduce the risk of low blood pressure. Treatment is discontinued once growth plates close, as determined by the treating pediatric endocrinologist or geneticist.
Voxzogo requires careful administration technique and monitoring for the following considerations.
Symptomatic decreases in blood pressure (dizziness, fatigue, nausea) can occur, particularly in infants and young children. Patients should be well hydrated (approximately 240-300 mL of fluid within the hour before injection) and have adequate food intake before each dose.
Mild injection site reactions are common; rotate injection sites to reduce risk.
Regular monitoring of growth plate status is required to determine when treatment should be discontinued.
Blood pressure monitoring, especially during the initial treatment period, is recommended by the treating specialist.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Voxzogo (vosoritide) is manufactured by BioMarin and is FDA-approved to increase linear growth in pediatric patients with achondroplasia with open growth plates.
Import of Voxzogo through a Named Patient Program requires a valid prescription from the treating pediatric endocrinologist or geneticist, confirmation of achondroplasia diagnosis and growth plate status, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Voxzogo directly from BioMarin's authorized supply chain to ensure product authenticity and regulatory compliance.
Voxzogo is sourced through verified, GDP-compliant, cold-chain channels from BioMarin's authorized supply chain to ensure authenticity and quality.
Voxzogo should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Voxzogo is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Voxzogo through NPP's regulated import pathway, with pediatric endocrinology and genetics specialists in major cities supporting the treatment process.
Leading pediatric endocrinology centers in Mumbai support achondroplasia diagnosis and treatment coordination for Voxzogo access.
Delhi's major hospitals assist patients with diagnostic confirmation and prescription support for Voxzogo.
Bangalore's specialist network offers access to achondroplasia treatment planning for eligible patients.
Chennai-based specialists coordinate Voxzogo access alongside comprehensive pediatric genetic care.
Hyderabad's care institutions support patients pursuing Voxzogo therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Voxzogo.
Pune-based specialists assist with diagnosis confirmation and Voxzogo treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Voxzogo.
Kochi's specialist units assist patients with the documentation needed for Voxzogo access.
Chandigarh's care centers support Voxzogo treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Voxzogo access process.
Lucknow-based centers assist patients pursuing Voxzogo therapy.
Bhubaneswar's institutions support access to Voxzogo for eligible patients.
Guwahati's specialists help coordinate Voxzogo access for patients across the Northeast.
Patients in other cities across India can also access Voxzogo through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
